Lynparza approved in EU in breast cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

AstraZeneca and Merck announced the European Commission has approved Lynparza as a monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, and who have HER2-negative locally advanced or metastatic breast cancer.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Twenty years ago, the discovery of epidermal growth factor receptor mutations as drivers of tumorigenesis and viable targets for therapeutic intervention marked the beginning of a new era in lung cancer diagnosis and treatment. Since then, the field has made remarkable progress towards developing more effective targeted treatments and immunotherapies that have significantly improved patient outcomes and survival.

Login